• Blog
  • Transcriptomics Market Report

    Transcriptomics Market Report

    Transcriptomics Market Report
    Report code - SR2196 Delivery - 2 Weeks
    Get Free Sample |
    Transcriptomics Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth Oppo See more...

    Market Insights

    The transcriptomics market was estimated at US$ 5.8 billion in 2021 and is expected to grow at a CAGR of 6.8% during 2022-2028 to reach US$ ~11.40 billion in 2028.

    Numerous uses of transcriptomics exist in illness analysis and diagnostics. Transcriptomics has evolved in recent years from purely research applications to diagnostic and clinical applications. The heterogeneity of cancers has been extensively studied using transcriptome analysis. Through unsupervised sampling and modelling of transcriptional states in single cells, massively parallel single-cell RNA sequence analysis has become a potent tool for understanding heterogeneity and studying rare cell types in cancer.

    The prevalence of chronic diseases like cancer and neuromuscular problem is rising, along with research and development in diagnostics and medication discovery in transcriptomics. These factors are also having a significant impact on the market's growth. Key market players' product releases, business expansions, partnerships, and acquisitions are anticipated to considerably fuel market growth. For instance, in February 2020, Caris Life Sciences introduced MI Transcriptome, which enables Whole Transcriptome Sequencing, as the newest component of its full genomic profile solution (WTS). In order to ensure that patients receive the most comprehensive tumour profiling approach possible from Caris, which evaluates DNA, RNA, and proteins to ensure patients receive the best possible care and correct therapies, MI Transcriptome uses the capabilities of high-throughput sequencing to gain insight into the RNA profiles of patients' tumours.

    Additionally, Dovetail Genomics announced in February 2020 that their Dovetail HiChIP and Micro-C Kits are now accessible worldwide. Companies are implementing plans to increase their global client base, which will accelerate market expansion.

    The market under study is therefore expected to increase during the course of the analysis period as a result of the aforementioned factors. However, a lack of technological awareness and strict regulatory requirements are expected to stymie industry expansion.

    The rise in demand for personalised medicine, increased R&D spending in pharmaceutical and biotechnology, government funding for omics, an increase in the use of RNA sequencing, and the development of new transcriptomics products by numerous key players are the main factors driving the growth of the global transcriptomics market. Increased attention on biomarker discovery and high demand for transcriptome in research and development activities have caused a spike in transcriptome production. According to National Human Genome Research Institute, a division of the National Institutes of Health (NIH), two projects—the Mouse Transcriptome Project and the Mammalian Gene Collection Initiative—created transcriptome resources for researchers all over the world. These two models are crucial for understanding human biology, which is expected to accelerate the expansion of the field.

    Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

    • High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals, a research article titled "High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals" published in Frontiers in Immunology Journal in July 2021, had an average of 97.02% of sequences with perfect matching barcodes and a mean quality score of 35.59 In the current study, each patient had an average of 45 billion bases sequenced, which is an increase of more than 10 billion from the prior studies. As a result, the growing application of transcriptomics in the field of COVID-19 is projected to have a significant effect on the segment's development.

    Segment Analysis

    Based on product type, technology, application, and geography, the market has been divided into segments. Consumables, instruments, and others are a few of the market segments for transcriptomics that have been created based on product type. The instruments segment is expected to grow at the fastest rate owing to high technological advancements.

    The transcriptomics market has been divided into microarray, real-time quantitative polymerase chain reaction (q-pcr), sequencing technologies categories based on technology.

    Based on application, the transcriptomics market has been divided into diagnostic and disease profiling, drug discovery, and others segments. The market's largest category is anticipated to be drug discovery segment. The main instrument for hastening disease diagnosis procedures is transcriptomics. There is a demand for better technology for diseases and diagnostics due to the fast rising global burden of chronic diseases including cancer and diabetes. For instance, the GLOBOCAN 2020 report states that there were around 19.2 million new cases and 9.9 cancer-related deaths worldwide. This rapidly expanding patient base will probably have a beneficial impact on the segment's expansion.

    The transcriptomics market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America is anticipated to be the transcriptomics market's largest region. It is anticipated that the leading market players' new releases, product approvals, partnerships, and acquisitions would help the nation's market grow. For instance, a multi-year agreement was entered into in January 2022 between Illumina Inc. and Nashville Biosciences LLC, a division of Vanderbilt University Medical Center (VUMC), to expedite the development of drugs through the use of next-generation sequencing and the creation of a clinical-genomic resource. These collaborations are anticipated to fuel the regional transcriptomics market's expansion.

    Key Players

    There is stiff competition in the transcriptomics market. The growth of the companies is directly dependent on industry conditions and government support. These companies differentiate their transcriptomics based on their quality and penetration in the target and emerging markets. Also, some major mergers and acquisitions in the industry recently have significantly influenced the competitive dynamics. For example:

    • BioSkryb Genomics introduced ResolveOME's Early Access Program (EAP) in May 2022. The entire genome and full-length mRNA transcripts of the entire transcriptome are amplified from the same cell using this integrated, single-cell approach.
    • In January 2022, Research Instruments Pte Ltd and Parse Biosciences teamed to offer Parse's Evercode Whole Transcriptome Kits (WTKs), Cell Fixation Kits, and Nuclei Fixation Kits in Singapore and Southeast Asia. Parse Biosciences is a provider of single-cell sequencing solutions for researchers.
    • HTG Molecular Diagnostics, Inc. (HTG) announced in August 2021 that its HTG Transcriptome Panel would go on sale in the US and EU. This panel measures over 20,000 mRNA targets using HTG EdgeSeq technology. The white paper published by the company indicated that the HTG Transcriptome Panel is repeatable and can be used to diagnose many cancers.
    • Rebus Biosystems introduced their spatial transcriptomics analysis platform "spatial omics" system in March 2021 with the goal of enabling researchers to examine individual cells' output across diverse tissue samples in more detail. Such product introductions will have a favourable impact on the market in the near future.
    • Parse Biosciences introduced the Single Cell Whole Transcriptome Kit in February 2021. The kit is now generally accessible to all academics in North America, having previously only been made available through Parse's early access programme.

    The overall competitive landscape has been affected due to these mergers and acquisitions. The following are the major players in the transcriptomics market:

    • 10x Genomics
    • Agilent Technologies Inc.
    • BGI Genomics
    • Bio-Rad Laboratories Inc.
    • Dovetail Genomics
    • F. Hoffmann-La Roche AG
    • Fluidigm Corporation
    • GE Healthcare
    • Illumina Inc.
    • Merck KGaA
    • Natera Inc.
    • PerkinElmer Inc.
    • Promega Corporation
    • Qiagen NV
    • Thermo Fisher Scientific

    Research Methodology

    This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both the qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    • Market structure: Overview, industry life cycle analysis, supply chain analysis
    • Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
    • Market trend and forecast analysis
    • Market segment trend and forecast
    • Competitive landscape and dynamics: Market share, product portfolio, product launches, etc.
    • Attractive market segments and associated growth opportunities
    • Emerging trends
    • Strategic growth opportunities for the existing and new players
    • Key success factors

    Frequently Asked Questions (FAQ)

    The transcriptomics market was valued at US$ 5.8 billion in 2021.

    The transcriptomics market reach at US$ ~11.40 billion in 2028.

    The market is growing at a CAGR of 6.8% over the forecast period.

    The major players in the transcriptomics market are 10x Genomics, Agilent Technologies Inc., BGI Genomics, Bio-Rad Laboratories Inc., Dovetail Genomics, F. Hoffmann-La Roche AG, Fluidigm Corporation, GE Healthcare, Illumina Inc., Merck KGaA, Natera Inc., PerkinElmer Inc., Promega Corporation, Qiagen NV, Thermo Fisher Scientific.

    The rise in demand for personalized medicine, increased R&D spending in pharmaceutical and biotechnology, government funding for omics, an increase in the use of RNA sequencing, and the development of new transcriptomics products by numerous key players are the main factors driving the growth of the global transcriptomics market.

    The transcriptomics market is studied from 2016 - 2028.

    In 2021, North America is anticipated to be the transcriptomics market's largest region.